Detalles de la búsqueda
1.
BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children.
J Clin Immunol
; 43(3): 557-567, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36383294
2.
Efficacy and safety of BT595 (10% human intravenous immunoglobulin) in adult patients with chronic immune thrombocytopenia.
Transfus Med
; 33(2): 165-173, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36448274
3.
Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease.
Vox Sang
; 117(10): 1153-1162, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35944615
4.
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.
Ann Rheum Dis
; 77(4): 495-499, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29343509
5.
Radiation Exposure and Contrast Volume Differ between Transapical and Transfemoral Aortic Valve Implantation with the Edwards SAPIEN Aortic Valve.
Thorac Cardiovasc Surg
; 63(6): 479-86, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25703634
6.
Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells.
Front Immunol
; 7: 11, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26834751
7.
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Clin Cancer Res
; 15(12): 4028-37, 2009 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19509164
Resultados
1 -
7
de 7
1
Próxima >
>>